• July 21, 2024

Atropos Health forms Life Science Advisory Board with pharma experts

The life sciences advisory board indicates a continued focus on regulatory complaint and transparent methods for rapid and responsible acceleration of innovation for life science partners on the Evidence Network.

The board will consist of executives from the world’s preeminent pharma companies including Moderna, Novartis among others.

This latest announcement comes hot on the heels of Atropos Health launching Geneva OS (Generative Evidence Acceleration Operating System) and ChatRWD (Real World Data) application​, the first Generative AI application incorporating direct Chat-to-Database capability, to help healthcare and life science leaders advance and accelerate evidence generation.

“I firmly believe that 2024 will be a revolutionary year in drug discovery and the acceleration of early drug development following the heels of innovation in AI,” said Brigham Hyde, co-founder and CEO, of Atropos Health.

“That’s why we’ve pulled together the brightest minds and the most effective companies in life sciences in order to supply organizations with the technology, data, and insights to bridge the evidence gap and bring more drugs to market.”

Members of the board include Barbara Salami, former vice president at Moderna and Gabriel Eichler, founder and managing director of Oak Health Partners, formerly of Novartis. They join Sean Khozin of Braven and Phyusion and Gerry McDougall former senior healthcare consulting partner at PwC.

Collaborating closely with Atropos Health’s partners, these advisory board members will spearhead the advocacy for Geneva OS and the Atropos Evidence Network to deliver auditable real-time insights ​​and support safe and compliant access to data across a federated network.

Leave a Reply

Your email address will not be published. Required fields are marked *